Overstimulation of the NMDA receptors by glutamate is implicated in neurodegenerative disorders, including Alzheimer’s disease (AD) 1
The NMDA receptor antagonist memantine is approved for the treatment of moderate/severe AD alone or in combination with cholinesterase inhibitors2-4
Memantine has been shown to reduce clinical deterioration in moderate/severe AD1
Furthermore, treatment with memantine has been shown to reduce symptoms such as agitation, aggression, irritability,and appetite disturbances5
Acess our Slide Deck on treatment principles of AD and learn more about pharmacological treatment of AD.
Related content
Social and physical exposome factors—like poverty, pollution, and inequality—accumulate over time, shaping biological aging and cognitive decline. Through inflammation and cellular stress, these exposures drive neurodegeneration, highlighting the need for longitudinal, integrative research.
The exposome reframes dementia as the product of cumulative physical and social exposures-like pollution, nutrition, and inequality-across life. These factors shape brain aging through inflammation and epigenetic change. Lifespan, global studies are key to equitable dementia prevention.
